{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:49Z","timestamp":1793672989737,"version":"4.5.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 108-2314-B-038-023"],"award-info":[{"award-number":["MOST 108-2314-B-038-023"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MOST","award":["107-2218-E-038-008"],"award-info":[{"award-number":["107-2218-E-038-008"]}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI MG-107-SP-07"],"award-info":[{"award-number":["NHRI MG-107-SP-07"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NSC","award":["NSC 111-2314-B-155 -001"],"award-info":[{"award-number":["NSC 111-2314-B-155 -001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glioblastoma multiforme (GBM) is an aggressive brain tumor with chemoresistant, immunosuppressive, and invasive properties. Despite standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, tumors inevitably recur in the peritumoral region. Targeting GBM-mediated immunosuppressive and invasive properties is a promising strategy to improve clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We utilized clinical and genomic data from the Taiwan GBM cohort and The Cancer Genome Atlas (TCGA) to analyze RNA sequencing data from patient tumor samples, determining the association of <jats:italic>interleukin-19<\/jats:italic> (<jats:italic>Il-19)<\/jats:italic> expression with survival and immunosuppressive activity. Gene set enrichment analysis (GSEA) was performed to assess the relationship between the enrichment levels of immune subsets and <jats:italic>Il-19<\/jats:italic> expression level, and Ingenuity Pathway Analysis (IPA) was used to predict immune responses. Cytokine array and single-cell RNA sequencing were used to examine the effects of IL-19 blockade on tumor immune microenvironment, including tumor-infiltrating leukocyte profiles, differentiation and immunosuppressive genes expression in tumor associated macrophages (TAM). CRISPR <jats:italic>Il-19<\/jats:italic>\n              <jats:sup>\u2212\/\u2212<\/jats:sup> cell lines and <jats:italic>Il-19<\/jats:italic>\n              <jats:sup>\u2212\/\u2212<\/jats:sup> mice were used to examine the role of IL-19 in tumor invasion and M2-like macrophage-mediated immunosuppression. Additionally, we developed novel cholesterol-polyethylene glycol-superparamagnetic iron oxide-IL-19 antibody nanoparticles (CHOL-PEG-SPIO-IL-19), characterized them using dynamic light scattering and transmission electron microscopy, Fourier-Transform Infrared spectroscopy, prussian blue assay, and conducted in vivo magnetic resonance imaging (MRI) in a human glioblastoma stem cell-derived GBM animal model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result<\/jats:title>\n            <jats:p>Genomic screening and IPA analysis identified IL-19 as a predicted immunosuppressive cytokine in the peritumoral region, associated with poor survival in patients with GBM. Blocking IL-19 significantly inhibited tumor progression of both TMZ-sensitive (TMZ-S) and TMZ-resistant (TMZ-R) GBM-bearing mice, and modulated the immune response within the GBM microenvironment. Single-cell transcriptome analysis reveal that IL-19 antibody treatment led to a marked increase in dendritic cells and monocyte\/macrophage subsets associated with interferon-gamma signaling pathways. IL-19 blockade promoted T cell activation and reprogrammed tumor-associated macrophages toward weakened pro-tumoral phenotypes with reduced Arginase 1 expression. <jats:italic>Il19<\/jats:italic>\n              <jats:sup>\u2212\/\u2212<\/jats:sup> M2-like bone marrow-derived macrophages with lower Arginase 1 level lost their ability to suppress CD8 T cell activation. These findings indicated that IL-19 suppression limits TAM-mediated immune suppression. Molecular studies revealed that IL-19 promotes TMZ-resistant GBM cell migration and invasion through a novel IL-19\/WISP1 signaling pathway. For clinical translation, we developed a novel CHOL-PEG-SPIO-IL-19 nanoparticles to target IL-19 expression in glioblastoma tissue. MRI imaging demonstrated enhanced targeting efficiency in brain tumors, with in vivo studies showing prominent hypointense areas in T2*-weighted MRI scans of tumor-bearing mice injected with CHOL-PEG-SPIO-IL-19, highlighting nanoparticle presence in IL-19-expressing regions. Prussian blue staining further confirmed the localization of these nanoparticles in tumor tissues, verifying their potential as a diagnostic tool for detecting IL-19 expression in glioblastoma. This system offers a theranostic approach, integrating diagnostic imaging and targeted therapy for IL-19-expressing GBM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>IL-19 is a promising theranostic target for reversing immunosuppression and restricting the invasive activity of chemoresistant GBM cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12929-025-01126-w","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T06:43:17Z","timestamp":1741416197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment"],"prefix":"10.1186","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-4702","authenticated-orcid":false,"given":"Gilbert Aaron","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Bo-Kai","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Tien","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Chieh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ying","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsiao","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yuo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Wen","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2011Wen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Wei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duen-Pang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho-Jen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiu-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Jien","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"1","key":"1126_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood SL, Powell SZ, Haviland DL, Parker Kerrigan BC, Lang FF, Prabhu SS, Huntoon KM, Jiang W, Kim BYS, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13(1):767.","journal-title":"Nat Commun"},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41698-018-0070-1","volume":"2","author":"M Abedalthagafi","year":"2018","unstructured":"Abedalthagafi M, Barakeh D, Foshay KM. Immunogenetics of glioblastoma: the future of personalized patient management. NPJ Precis Oncol. 2018;2:27.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"1126_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/ibd.21151","volume":"16","author":"YT Azuma","year":"2010","unstructured":"Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM, Murphy AJ, Nakajima H, Karow M, Takeuchi T. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis. 2010;16(6):1017\u201328.","journal-title":"Inflamm Bowel Dis"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fonc.2020.00494","volume":"10","author":"N Bergmann","year":"2020","unstructured":"Bergmann N, Delbridge C, Gempt J, Feuchtinger A, Walch A, Schirmer L, Bunk W, Aschenbrenner T, Liesche-Starnecker F, Schlegel J. The intratumoral heterogeneity reflects the intertumoral subtypes of glioblastoma multiforme: a regional immunohistochemistry analysis. Front Oncol. 2020;10:494.","journal-title":"Front Oncol"},{"issue":"12","key":"1126_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00262-011-1069-4","volume":"60","author":"G Cantini","year":"2011","unstructured":"Cantini G, Pisati F, Mastropietro A, Frattini V, Iwakura Y, Finocchiaro G, Pellegatta S. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother. 2011;60(12):1739\u201350.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1126_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Network TR, Noushmehr H, Iavarone A, Verhaak RG. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550\u201363.","journal-title":"Cell"},{"key":"1126_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.747690","volume":"11","author":"N Di Ianni","year":"2021","unstructured":"Di Ianni N, Maffezzini M, Eoli M, Pellegatta S. Revisiting the immunological aspects of temozolomide considering the genetic landscape and the immune microenvironment composition of glioblastoma. Front Oncol. 2021;11: 747690.","journal-title":"Front Oncol"},{"issue":"3","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S Dordevic","year":"2022","unstructured":"Dordevic S, Gonzalez MM, Conejos-Sanchez I, Carreira B, Pozzi S, Acurcio RC, Satchi-Fainaro R, Florindo HF, Vicent MJ. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500\u201325.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"1126_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0028","volume":"1","author":"T Doucette","year":"2013","unstructured":"Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112\u201322.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"1126_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1215\/15228517-2006-006","volume":"8","author":"A El Andaloussi","year":"2006","unstructured":"El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8(3):234\u201343.","journal-title":"Neuro Oncol"},{"issue":"15","key":"1126_CR11","doi-asserted-by":"publisher","first-page":"11221","DOI":"10.1074\/jbc.M611871200","volume":"282","author":"D Fang","year":"2007","unstructured":"Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282(15):11221\u20139.","journal-title":"J Biol Chem"},{"issue":"4","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1126_CR13","volume":"2","author":"K Gabunia","year":"2015","unstructured":"Gabunia K, Autieri MV. Interleukin-19 can enhance angiogenesis by Macrophage Polarization. Macrophage (Houst). 2015;2(1): e562.","journal-title":"Macrophage (Houst)"},{"issue":"9","key":"1126_CR14","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.4049\/jimmunol.1202246","volume":"189","author":"SP Gadani","year":"2012","unstructured":"Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. J Immunol. 2012;189(9):4213\u20139.","journal-title":"J Immunol"},{"issue":"5","key":"1126_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cytogfr.2010.08.005","volume":"21","author":"G Gallagher","year":"2010","unstructured":"Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev. 2010;21(5):345\u201352.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"20","key":"1126_CR16","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1016\/j.biomaterials.2012.03.058","volume":"33","author":"H Gao","year":"2012","unstructured":"Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X, Zhang Q. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33(20):5115\u201323.","journal-title":"Biomaterials"},{"issue":"1","key":"1126_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S Gavas","year":"2021","unstructured":"Gavas S, Quazi S, Karpinski TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):173.","journal-title":"Nanoscale Res Lett"},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","volume":"11","author":"TM Grzywa","year":"2020","unstructured":"Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.","journal-title":"Front Immunol"},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3389\/fonc.2020.01015","volume":"10","author":"C Hao","year":"2020","unstructured":"Hao C, Chen G, Zhao H, Li Y, Chen J, Zhang H, Li S, Zhao Y, Chen F, Li W, Jiang WG. PD-L1 expression in glioblastoma, the clinical and prognostic significance: a systematic literature review and meta-analysis. Front Oncol. 2020;10:1015.","journal-title":"Front Oncol"},{"issue":"43","key":"1126_CR20","doi-asserted-by":"publisher","first-page":"74170","DOI":"10.18632\/oncotarget.18819","volume":"8","author":"S Heynckes","year":"2017","unstructured":"Heynckes S, Gaebelein A, Haaker G, Grauvogel J, Franco P, Mader I, Carro MS, Prinz M, Delev D, Schnell O, Heiland DH. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget. 2017;8(43):74170\u20137.","journal-title":"Oncotarget"},{"key":"1126_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.615898","volume":"12","author":"H Horiuchi","year":"2021","unstructured":"Horiuchi H, Parajuli B, Komiya H, Ogawa Y, Jin S, Takahashi K, Azuma YT, Tanaka F, Suzumura A, Takeuchi H. Interleukin-19 abrogates experimental autoimmune encephalomyelitis by attenuating antigen-presenting cell activation. Front Immunol. 2021;12: 615898.","journal-title":"Front Immunol"},{"issue":"3","key":"1126_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118640","volume":"10","author":"H Horiuchi","year":"2015","unstructured":"Horiuchi H, Parajuli B, Wang Y, Azuma YT, Mizuno T, Takeuchi H, Suzumura A. Interleukin-19 acts as a negative autocrine regulator of activated microglia. PLoS ONE. 2015;10(3): e0118640.","journal-title":"PLoS ONE"},{"issue":"3","key":"1126_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1158\/1078-0432.CCR-11-1532","volume":"18","author":"CH Hsing","year":"2012","unstructured":"Hsing CH, Cheng HC, Hsu YH, Chan CH, Yeh CH, Li CF, Chang MS. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clin Cancer Res. 2012;18(3):713\u201325.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1126_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075254","volume":"8","author":"CH Hsing","year":"2013","unstructured":"Hsing CH, Kwok FA, Cheng HC, Li CF, Chang MS. Inhibiting interleukin-19 activity ameliorates esophageal squamous cell carcinoma progression. PLoS ONE. 2013;8(10): e75254.","journal-title":"PLoS ONE"},{"issue":"1","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/10717544.2016.1233590","volume":"24","author":"X Hu","year":"2017","unstructured":"Hu X, Yang F, Liao Y, Li L, Zhang L. Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations. Drug Deliv. 2017;24(1):121\u201332.","journal-title":"Drug Deliv"},{"issue":"1","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res. 2024;43(1):23.","journal-title":"J Exp Clin Cancer Res"},{"issue":"303","key":"1126_CR27","doi-asserted-by":"publisher","first-page":"303ra138","DOI":"10.1126\/scitranslmed.aaa7582","volume":"7","author":"H Itakura","year":"2015","unstructured":"Itakura H, Achrol AS, Mitchell LA, Loya JJ, Liu T, Westbroek EM, Feroze AH, Rodriguez S, Echegaray S, Azad TD, Yeom KW, Napel S, Rubin DL, Chang SD, Harsh GRT, Gevaert O. Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med. 2015;7(303):303ra138.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1126_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3892\/ijo.2017.4119","volume":"51","author":"D Jing","year":"2017","unstructured":"Jing D, Zhang Q, Yu H, Zhao Y, Shen L. Identification of WISP1 as a novel oncogene in glioblastoma. Int J Oncol. 2017;51(4):1261\u201370.","journal-title":"Int J Oncol"},{"key":"1126_CR29","doi-asserted-by":"publisher","first-page":"1273986","DOI":"10.3389\/fimmu.2023.1273986","volume":"14","author":"I Kang","year":"2023","unstructured":"Kang I, Kim Y, Lee HK. gammadelta T cells as a potential therapeutic agent for glioblastoma. Front Immunol. 2023;14:1273986.","journal-title":"Front Immunol"},{"key":"1126_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0757-9","volume":"14","author":"MS Kindy","year":"2016","unstructured":"Kindy MS, Yu J, Zhu H, Smith MT, Gattoni-Celli S. A therapeutic cancer vaccine against GL261 murine glioma. J Transl Med. 2016;14:1.","journal-title":"J Transl Med"},{"issue":"6","key":"1126_CR31","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","volume":"11","author":"S Kohsaka","year":"2012","unstructured":"Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther. 2012;11(6):1289\u201399.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1535-7163.MCT-05-0453","volume":"5","author":"D Koul","year":"2006","unstructured":"Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006;5(3):637\u201344.","journal-title":"Mol Cancer Ther"},{"key":"1126_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cyto.2018.04.005","volume":"108","author":"NP Kumar","year":"2018","unstructured":"Kumar NP, Moideen K, Banurekha VV, Nair D, Babu S. Modulation of Th1\/Tc1 and Th17\/Tc17 responses in pulmonary tuberculosis by IL-20 subfamily of cytokines. Cytokine. 2018;108:190\u20136.","journal-title":"Cytokine"},{"key":"1126_CR34","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.2147\/IJN.S310464","volume":"16","author":"GA Lee","year":"2021","unstructured":"Lee GA, Lin WL, Kuo DP, Li YT, Chang YW, Chen YC, Huang SW, Hsu JBK, Chen CY. Detection of PD-L1 expression in temozolomide-resistant glioblastoma by using PD-L1 antibodies conjugated with lipid-coated superparamagnetic iron oxide. Int J Nanomed. 2021;16:5233\u201346.","journal-title":"Int J Nanomed"},{"key":"1126_CR35","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.2147\/IJN.S310464","volume":"16","author":"GA Lee","year":"2021","unstructured":"Lee GA, Lin WL, Kuo DP, Li YT, Chang YW, Chen YC, Huang SW, Hsu JB, Chen CY. Detection of PD-L1 expression in temozolomide-resistant glioblastoma by using PD-L1 antibodies conjugated with lipidcoated superparamagnetic iron oxide. Int J Nanomed. 2021;16:5233\u201346.","journal-title":"Int J Nanomed"},{"issue":"3","key":"1126_CR36","doi-asserted-by":"publisher","first-page":"C457","DOI":"10.1152\/ajpcell.00247.2020","volume":"319","author":"T Leigh","year":"2020","unstructured":"Leigh T, Scalia RG, Autieri MV. Resolution of inflammation in immune and nonimmune cells by interleukin-19. Am J Physiol Cell Physiol. 2020;319(3):C457\u201364.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"10","key":"1126_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/neuonc\/nov119","volume":"17","author":"JM Lemee","year":"2015","unstructured":"Lemee JM, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don\u2019t forget the peritumoral brain zone. Neuro Oncol. 2015;17(10):1322\u201332.","journal-title":"Neuro Oncol"},{"issue":"5","key":"1126_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/mps5050068","volume":"5","author":"BW Lewis","year":"2022","unstructured":"Lewis BW, Patial S, Saini Y. In vitro screening method for characterization of macrophage activation responses. Methods Protoc. 2022;5(5):68.","journal-title":"Methods Protoc"},{"issue":"6","key":"1126_CR39","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3892\/ijmm.2015.2390","volume":"36","author":"J Li","year":"2015","unstructured":"Li J, Ye L, Owen S, Weeks HP, Zhang Z, Jiang WG. Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review). Int J Mol Med. 2015;36(6):1451\u201363.","journal-title":"Int J Mol Med"},{"issue":"1","key":"1126_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","volume":"31","author":"Y-R Li","year":"2024","unstructured":"Li Y-R, Halladay T, Yang L. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies. J Biomed Sci. 2024;31(1):5.","journal-title":"J Biomed Sci"},{"issue":"8","key":"1126_CR41","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.biocel.2012.04.017","volume":"44","author":"T Liu","year":"2012","unstructured":"Liu T, Li Y, Lin K, Yin H, He B, Zheng M, Wang G. Regulation of S100A4 expression via the JAK2-STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia. Int J Biochem Cell Biol. 2012;44(8):1337\u201345.","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"1126_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354\u201375.","journal-title":"Cell Mol Immunol"},{"key":"1126_CR43","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fonc.2018.00578","volume":"8","author":"J Lynes","year":"2018","unstructured":"Lynes J, Sanchez V, Dominah G, Nwankwo A, Nduom E. Current options and future directions in immune therapy for glioblastoma. Front Oncol. 2018;8:578.","journal-title":"Front Oncol"},{"issue":"52","key":"1126_CR44","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, Wasik MA. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7\u2013H1). Proc Natl Acad Sci U S A. 2008;105(52):20852\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1126_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","volume":"4","author":"BE McIntosh","year":"2015","unstructured":"McIntosh BE, Brown ME, Duffin BM, Maufort JP, Vereide DT, Slukvin II, Thomson JA. Nonirradiated NOD, B6.SCID Il2rgamma-\/- Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells. Stem Cell Reports. 2015;4(2):171\u201380.","journal-title":"Stem Cell Reports"},{"key":"1126_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3389\/fimmu.2020.00737","volume":"11","author":"Y Mi","year":"2020","unstructured":"Mi Y, Guo N, Luan J, Cheng J, Hu Z, Jiang P, Jin W, Gao X. The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment. Front Immunol. 2020;11:737.","journal-title":"Front Immunol"},{"issue":"3","key":"1126_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0090-3019(98)00056-1","volume":"51","author":"G Nagashima","year":"1999","unstructured":"Nagashima G, Suzuki R, Hokaku H, Takahashi M, Miyo T, Asai J, Nakagawa N, Fujimoto T. Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. Surg Neurol. 1999;51(3):292\u20139.","journal-title":"Surg Neurol"},{"issue":"2","key":"1126_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EK Nduom","year":"2016","unstructured":"Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195\u2013205.","journal-title":"Neuro Oncol"},{"key":"1126_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112840","volume":"149","author":"F Niu","year":"2022","unstructured":"Niu F, Yu Y, Li Z, Ren Y, Li Z, Ye Q, Liu P, Ji C, Qian L, Xiong Y. Arginase: an emerging and promising therapeutic target for cancer treatment. Biomed Pharmacother. 2022;149: 112840.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1126_CR50","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41467-021-21407-w","volume":"12","author":"N Ochocka","year":"2021","unstructured":"Ochocka N, Segit P, Walentynowicz KA, Wojnicki K, Cyranowski S, Swatler J, Mieczkowski J, Kaminska B. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat Commun. 2021;12(1):1151.","journal-title":"Nat Commun"},{"issue":"Suppl 4","key":"1126_CR51","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol. 2015;17(Suppl 4):iv1\u201362.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1126_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-012-1312-7","volume":"62","author":"M Paladugu","year":"2013","unstructured":"Paladugu M, Thakur A, Lum LG, Mittal S, Parajuli P. Generation and immunologic functions of Th17 cells in malignant gliomas. Cancer Immunol Immunother. 2013;62(1):75\u201386.","journal-title":"Cancer Immunol Immunother"},{"key":"1126_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.582106","volume":"11","author":"JRD Pearson","year":"2020","unstructured":"Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, Pockley AG, McArdle SEB. Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Front Immunol. 2020;11: 582106.","journal-title":"Front Immunol"},{"issue":"3","key":"1126_CR54","first-page":"311","volume":"3","author":"XH Peng","year":"2008","unstructured":"Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311\u201321.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1126_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11060-012-0983-4","volume":"111","author":"K Petrecca","year":"2013","unstructured":"Petrecca K, Guiot MC, Panet-Raymond V, Souhami L. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol. 2013;111(1):19\u201323.","journal-title":"J Neurooncol"},{"key":"1126_CR56","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3389\/fimmu.2020.01036","volume":"11","author":"P Rochigneux","year":"2020","unstructured":"Rochigneux P, Garcia AJ, Chanez B, Madroszyk A, Olive D, Garon EB. Medical treatment of lung cancer: can immune cells predict the response? A systematic review. Front Immunol. 2020;11:1036.","journal-title":"Front Immunol"},{"issue":"1022","key":"1126_CR57","doi-asserted-by":"publisher","first-page":"20120414","DOI":"10.1259\/bjr.20120414","volume":"86","author":"J Sherriff","year":"2013","unstructured":"Sherriff J, Tamangani J, Senthil L, Cruickshank G, Spooner D, Jones B, Brookes C, Sanghera P. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol. 2013;86(1022):20120414.","journal-title":"Br J Radiol"},{"key":"1126_CR58","first-page":"17","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma\u2014a comprehensive review. Cancer Drug Resist. 2021;4:17\u201343.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"1126_CR59","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/s41467-020-16827-z","volume":"11","author":"W Tao","year":"2020","unstructured":"Tao W, Chu C, Zhou W, Huang Z, Zhai K, Fang X, Huang Q, Zhang A, Wang X, Yu X, Huang H, Wu Q, Sloan AE, Yu JS, Li X, Stark GR, Rich JN, Bao S. Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. Nat Commun. 2020;11(1):3015.","journal-title":"Nat Commun"},{"key":"1126_CR60","doi-asserted-by":"crossref","unstructured":"Tsou YH, Zhang XQ, Zhu H, Syed S, Xu X. Drug delivery to the brain across the blood-brain barrier using nanomaterials. Small. 2017;13(43).","DOI":"10.1002\/smll.201701921"},{"issue":"4","key":"1126_CR61","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1172\/JCI60083","volume":"123","author":"D Vasquez-Dunddel","year":"2013","unstructured":"Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H, Pardoll D, Kim Y. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580\u20139.","journal-title":"J Clin Invest"},{"key":"1126_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1755-8794-5-41","volume":"5","author":"E Vauleon","year":"2012","unstructured":"Vauleon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu DC, Menei P, Mosser J, Quillien V, Aubry M. Immune genes are associated with human glioblastoma pathology and patient survival. BMC Med Genomics. 2012;5:41.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"1126_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","volume":"38","author":"X Wang","year":"2019","unstructured":"Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019;38(1):87.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1126_CR64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41419-021-03568-0","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Lu J, Guo G, Yu J. Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death Dis. 2021;12(4):299.","journal-title":"Cell Death Dis"},{"key":"1126_CR65","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.2147\/IJN.S321984","volume":"16","author":"H Wei","year":"2021","unstructured":"Wei H, Hu Y, Wang J, Gao X, Qian X, Tang M. Superparamagnetic iron oxide nanoparticles: cytotoxicity, metabolism, and cellular behavior in biomedicine applications. Int J Nanomed. 2021;16:6097\u2013113.","journal-title":"Int J Nanomed"},{"issue":"8","key":"1126_CR66","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/jpm11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771.","journal-title":"J Pers Med"},{"issue":"18","key":"1126_CR67","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1016\/j.biomaterials.2011.02.044","volume":"32","author":"H Xin","year":"2011","unstructured":"Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X. Angiopep-conjugated poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials. 2011;32(18):4293\u2013305.","journal-title":"Biomaterials"},{"issue":"2","key":"1126_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10014-010-0275-7","volume":"27","author":"T Yamahara","year":"2010","unstructured":"Yamahara T, Numa Y, Oishi T, Kawaguchi T, Seno T, Asai A, Kawamoto K. Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathol. 2010;27(2):81\u20137.","journal-title":"Brain Tumor Pathol"},{"issue":"4","key":"1126_CR69","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41587-019-0055-9","volume":"37","author":"J Zhang","year":"2019","unstructured":"Zhang J, Bajari R, Andric D, Gerthoffert F, Lepsa A, Nahal-Bose H, Stein LD, Ferretti V. The international cancer genome consortium data portal. Nat Biotechnol. 2019;37(4):367\u20139.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1126_CR70","doi-asserted-by":"publisher","first-page":"20276","DOI":"10.1038\/s41598-019-56696-1","volume":"9","author":"JF Zhang","year":"2019","unstructured":"Zhang JF, Tao T, Wang K, Zhang GX, Yan Y, Lin HR, Li Y, Guan MW, Yu JJ, Wang XD. IL-33\/ST2 axis promotes glioblastoma cell invasion by accumulating tenascin-C. Sci Rep. 2019;9(1):20276.","journal-title":"Sci Rep"},{"issue":"6","key":"1126_CR71","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/bm5003009","volume":"15","author":"Y Zhong","year":"2014","unstructured":"Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromol. 2014;15(6):1955\u201369.","journal-title":"Biomacromol"},{"issue":"8","key":"1126_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.63.8.9","volume":"63","author":"J Zou","year":"2022","unstructured":"Zou J, Tan W, Li B, Wang Z, Li Y, Zeng J, Jiang B, Yoshida S, Zhou Y. Interleukin-19 promotes retinal neovascularization in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2022;63(8):9.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01126-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:04:02Z","timestamp":1745827442000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-025-01126-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01126-w","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The affiliations of the corresponding authors are corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Taipei Medical University (no. N201603086). All animal care and experimental procedures were approved by the Ethics Committee of Taipei Medical University and conducted in strict accordance with the ARRIVE Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}